Last reviewed · How we verify
Zeposia
At a glance
| Generic name | Zeposia |
|---|---|
| Sponsor | Kessler Foundation |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects
- An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice (PHASE4)
- Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis (PHASE3)
- A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
- Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients
- A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
- A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zeposia CI brief — competitive landscape report
- Zeposia updates RSS · CI watch RSS
- Kessler Foundation portfolio CI